Fig. 1From: Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE studyPatient disposition. MDS myelodysplastic syndrome, TDT transfusion-dependent thalassemia. aThe 34 patients who completed the study had received treatment for at least 24 monthsBack to article page